Paula T Lyra1,2, Edvaldo Souza3,4, Ana Carla A Moura3,5, Marina C Matta6, Leuridan C Torres6, Antonio Victor Campos Coelho7, Maria Ângela W Rocha5, Luiz Arraes3,8, João Bosco Oliveira7. 1. Department of Clinical Immunology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil. paulatlyra@gmail.com. 2. Children's Department of Infectious Disease, Oswaldo Cruz University Hospital (HUOC), Universidade de Pernambuco (UPE), Recife, PA, Brazil. paulatlyra@gmail.com. 3. Department of Clinical Immunology, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Pernambuco, Brazil. 4. Faculdade Pernambucana de Saúde (FPS), Recife, PA, Brazil. 5. Children's Department of Infectious Disease, Oswaldo Cruz University Hospital (HUOC), Universidade de Pernambuco (UPE), Recife, PA, Brazil. 6. Translational Research Laboratory Prof. C. A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, PE, Brazil. 7. Hospital Israelita Albert Einstein, São Paulo, SP, Brazil. 8. Universidade Federal de Pernambuco (UFPE), Recife, PA, Brazil.
Abstract
OBJECTIVE: The Bacille Calmette-Guérin (BCG) vaccine is routinely applied in Brazil. Adverse events (AE) may occur in patients with inborn or acquired immunodeficiencies, varying between local (BCGitis) or disseminated (BCGosis) reactions. We evaluated 53 individuals with local or disseminated adverse events to BCG vaccination to assess if they had inborn errors of immunity (IEI). METHODS: Patients diagnosed with an adverse event following BCG vaccination between 2014 and 2017 were included in the study. We collected clinical data, immunophenotyped T and B lymphocytes, and natural killer cells (NK), assessed oxidative function of neutrophils through dihydrorhodamine (DHR) 123 testing, and genotyped 361 genes related to IEI through targeted (panel) sequencing. RESULTS: The median age of the 53 individuals was four months (IQ 1.5-12), and 52.8% were male. Forty-eight (90.6%) individuals presented only locoregional AE and five (9.4%) presented both locoregional and disseminated AE. Nine (16.9%) patients were diagnosed with an IEI. Four of them presented BCGitis and five presented BCGosis after BCG vaccination. Clinically, four presented chronic granulomatous disease (CGD), three Mendelian susceptibility to mycobacterial disease (MSMD), and two severe combined immunodeficiency (SCID). Patients with IEI had a higher frequency of systemic symptomatology (p = 0.002), history of other infections (p < 0.001), parental consanguinity (p = 0.01), familial history of sick siblings (p < 0.001), or early deaths in the family (p < 0.01). CONCLUSION: There is a high frequency of IEI in patients with locoregional and disseminated adverse events to BCG vaccination, revealing the need for the investigation of IEI accompanied by clinical and familial inquiry.
OBJECTIVE: The Bacille Calmette-Guérin (BCG) vaccine is routinely applied in Brazil. Adverse events (AE) may occur in patients with inborn or acquired immunodeficiencies, varying between local (BCGitis) or disseminated (BCGosis) reactions. We evaluated 53 individuals with local or disseminated adverse events to BCG vaccination to assess if they had inborn errors of immunity (IEI). METHODS: Patients diagnosed with an adverse event following BCG vaccination between 2014 and 2017 were included in the study. We collected clinical data, immunophenotyped T and B lymphocytes, and natural killer cells (NK), assessed oxidative function of neutrophils through dihydrorhodamine (DHR) 123 testing, and genotyped 361 genes related to IEI through targeted (panel) sequencing. RESULTS: The median age of the 53 individuals was four months (IQ 1.5-12), and 52.8% were male. Forty-eight (90.6%) individuals presented only locoregional AE and five (9.4%) presented both locoregional and disseminated AE. Nine (16.9%) patients were diagnosed with an IEI. Four of them presented BCGitis and five presented BCGosis after BCG vaccination. Clinically, four presented chronic granulomatous disease (CGD), three Mendelian susceptibility to mycobacterial disease (MSMD), and two severe combined immunodeficiency (SCID). Patients with IEI had a higher frequency of systemic symptomatology (p = 0.002), history of other infections (p < 0.001), parental consanguinity (p = 0.01), familial history of sick siblings (p < 0.001), or early deaths in the family (p < 0.01). CONCLUSION: There is a high frequency of IEI in patients with locoregional and disseminated adverse events to BCG vaccination, revealing the need for the investigation of IEI accompanied by clinical and familial inquiry.
Authors: Beatriz E Marciano; Chiung-Yu Huang; Gyan Joshi; Nima Rezaei; Beatriz Costa Carvalho; Zoe Allwood; Aydan Ikinciogullari; Shereen M Reda; Andrew Gennery; Vojtech Thon; Francisco Espinosa-Rosales; Waleed Al-Herz; Oscar Porras; Anna Shcherbina; Anna Szaflarska; Şebnem Kiliç; Jose L Franco; Andrea C Gómez Raccio; Persio Roxo; Isabel Esteves; Nermeen Galal; Anete Sevciovic Grumach; Salem Al-Tamemi; Alisan Yildiran; Julio C Orellana; Masafumi Yamada; Tomohiro Morio; Diana Liberatore; Yoshitoshi Ohtsuka; Yu-Lung Lau; Ryuta Nishikomori; Carlos Torres-Lozano; Juliana T L Mazzucchelli; Maria M S Vilela; Fabiola S Tavares; Luciana Cunha; Jorge A Pinto; Sara E Espinosa-Padilla; Leticia Hernandez-Nieto; Reem A Elfeky; Tadashi Ariga; Heike Toshio; Figen Dogu; Funda Cipe; Renata Formankova; M Enriqueta Nuñez-Nuñez; Liliana Bezrodnik; Jose Gonçalo Marques; María I Pereira; Viviana Listello; Mary A Slatter; Zohreh Nademi; Danuta Kowalczyk; Thomas A Fleisher; Graham Davies; Bénédicte Neven; Sergio D Rosenzweig Journal: J Allergy Clin Immunol Date: 2014-04 Impact factor: 10.793
Authors: C M Jacob; A C Pastorino; A M Azevedo; H H Marques; H K Sato; L Ferrazole; M Z Aquino; P T Sakane; A S Grumach Journal: J Investig Allergol Clin Immunol Date: 1996 May-Jun Impact factor: 4.333
Authors: J T L Mazzucchelli; C Bonfim; G G Castro; A A Condino-Neto; N M X Costa; L Cunha; E O Dantas; V M Dantas; M I de Moraes-Pinto; J F Fernandes; H C Goes; E Goudouris; A S Grumach; L M B Guirau; G Kuntze; M C Mallozzi; F P Monteiro; L S L Moraes; V Nudelman; J A Pinto; M C V Rizzo; A C Porto-Neto; P Roxo-Junior; M Ruiz; V E V Rullo; A Seber; O A Takano; F S Tavares; E Toledo; M M S Vilela; B T Costa-Carvalho Journal: J Investig Allergol Clin Immunol Date: 2014 Impact factor: 4.333
Authors: Abdulkarim Abdullah Alrabiaah; Sarah Suliman Alsubaie; Elham Issa Bukhari; Ashry Gad; Fahad Abdullah Alzamel Journal: Ann Saudi Med Date: 2012 Jan-Feb Impact factor: 1.526